Galapagos (NASDAQ:GLPG) and Vivesto (OTCMKTS:OASMY) Head to Head Survey

Galapagos (NASDAQ:GLPG) and Vivesto (OTCMKTS:OASMY) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Earnings and Valuation

This table compares Galapagos and Vivesto’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galapagos	$259.40 million	7.48	$229.12 million	($2.29)	-12.86
Vivesto	$100,000.00	35.87	-$35.35 million	N/A	N/A

Galapagos has higher revenue and earnings than Vivesto.

Institutional & Insider Ownership

32.5% of Galapagos shares are owned by institutional investors. 2.9% of Galapagos shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for Galapagos and Vivesto, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galapagos	1	3	1	0	2.00
Vivesto	0	0	0	0	N/A

Galapagos presently has a consensus target price of $34.50, suggesting a potential upside of 17.15%. Given Galapagos’ higher probable upside, analysts plainly believe Galapagos is more favorable than Vivesto.

Profitability

This table compares Galapagos and Vivesto’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Galapagos	-26.25%	-2.60%	-1.46%
Vivesto	N/A	-99.73%	-91.27%

Volatility and Risk

Galapagos has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500. Comparatively, Vivesto has a beta of 21.1, suggesting that its share price is 2,010% more volatile than the S&P 500.

Summary

Galapagos beats Vivesto on 8 of the 11 factors compared between the two stocks.

About Galapagos

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of?various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG3667 that has completed Phase 1b trial; and GLPG5101 and GLPG5201, CD19 CAR-T product candidate manufactures at point-of-care, that is in Phase I/II in relapsed/refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

About Vivesto

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.